Remove tag work-environment
article thumbnail

What you need to know about treating skin tags

The Checkup by Singlecare

Skin tags are one of those things you probably don’t think about until you spot one. At first glance, you may fear it’s a symptom of psoriasis , eczema , HPV warts, or skin cancer —but skin tags are common, noncancerous, and essentially harmless. Read on to see what experts say about the following 13 home remedies for skin tags.

FDA 115
article thumbnail

5 Things I Love About The MAD-ID Conference, The Antimicrobial Stewardship Meeting

IDStewardship

It has claimed the tag line “The Antimicrobial Stewardship Meeting.” Generating Ideas from Poster Session Conversations This is not a conference with a huge quantity of research posters, but the quality of the work presented at MAD-ID is high. I have been following her work for many years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. The key is adapting existing legacy and traditional printed material for the digital environment.”. Virtual connections.

article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. They also employ exceptionally high levels of ‘test and learn’ activities to understand which campaigns work and should be upscaled.

article thumbnail

bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval

pharmaphorum

The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the pricing and reimbursement environment there was too “hostile.”

FDA 52
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. BL: [It is] distressing as a scientist to work on something that patients cannot access. Currently, all approved CAR-T therapies are autologous, where T cells taken from patients are modified and then re-infused.

FDA 59